公司资料
Pliant Therapeutics 股价、新闻与催化剂
- 股票代码:
- PLRX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.10 USD (+2.80%)
收盘价
最后更新: 2026年8月17日
71.8M USD
市值
股价为何变动
The latest monitored company update is “Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors.” The corresponding closing-price reaction is not yet available.
公司概览
Integrin-Targeted Drug Discovery
Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery.
PLN-101095
PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1 integrins. It is designed to block TGF-β activation in the tumor microenvironment and overcome resistance to immune checkpoint inhibitors.
FORTIFY Expansion Study
The Phase 1b FORTIFY study evaluates PLN-101095 with pembrolizumab in checkpoint-inhibitor-refractory solid tumors. Expansion cohorts include non-small cell lung cancer, clear-cell renal-cell carcinoma, and tumors with high tumor mutational burden.
Integrin-Targeted Delivery Platform
Pliant is also using integrin receptor-binding molecules to deliver payloads to specific tissues. Preclinical programs are evaluating siRNA delivery to skeletal muscle cells, adipocytes, and renal cells.
未来催化剂
- Interim data from the Phase 1b FORTIFY expansion study in 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。